Inflammation resolution and specialized pro-resolving lipid mediators in chronic rhinosinusitis

References

• Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. Otolaryngol Head Neck Surg. 2015 Apr;152(S2):S1–39. PMID: 25832968. doi: 10.1177/0194599815572097
   PubMedGoogle Scholar
• Orlandi RR, Kingdom TT, Hwang PH, et al. International consensus statement on allergy and rhinology: rhinosinusitis. Int Forum Allergy Rhinol. 2016 Feb;6(Suppl 1):S22–209. PMID: 26889651. doi: 10.1002/alr.21695
   PubMed Web of Science ®Google Scholar
• Cho SH, Hamilos DL, Han DH, et al. Phenotypes of chronic rhinosinusitis. J Allergy Clin Immunol Pract. 2020 May;8(5):1505–1511. PMID: 32389275; PMCID: PMC7696652. doi: 10.1016/j.jaip.2019.12.021
   PubMed Web of Science ®Google Scholar
• Bachert C, Marple B, Schlosser RJ, et al. Adult chronic rhinosinusitis. Nat Rev Dis Primers. 2020 Oct 29;6(1):86. PMID: 33122665. doi: 10.1038/s41572-020-00218-1
   PubMed Web of Science ®Google Scholar
• Schleimer RP. Immunopathogenesis of chronic rhinosinusitis and nasal polyposis. Annu Rev Pathol. 2017 Jan 24;12(1):331–357. Epub 2016 Dec 5. PMID: 27959637; PMCID: PMC5514544. doi: 10.1146/annurev-pathol-052016-100401
   PubMedGoogle Scholar
• Meltzer EO, Hamilos DL, Hadley JA, et al. American Academy of Allergy, Asthma and Immunology; American Academy of Otolaryngic Allergy; American Academy of Otolaryngology-Head and Neck Surgery; American College of Allergy, Asthma and Immunology; American Rhinologic Society. Rhinosinusitis: establishing definitions for clinical research and patient care. Otolaryngol Head Neck Surg. 2004 Dec;131(6 Suppl):S1–62. PMID: 15577816; PMCID: PMC7118860. doi: 10.1016/j.otohns.2004.09.067
   PubMed Web of Science ®Google Scholar
• Saliba J, Fnais N, Tomaszewski M, et al. The role of trigeminal function in the sensation of nasal obstruction in chronic rhinosinusitis. Laryngoscope. 2016 May;126(5):E174–8. Epub 2016 Mar 1. PMID: 26926075. doi: 10.1002/lary.25952
   PubMed Web of Science ®Google Scholar
• Vickery TW, Armstrong M, Kofonow JM, et al. Altered tissue specialized pro-resolving mediators in chronic rhinosinusitis. Prostaglandins, Leukotrienes Essent Fatty Acids. 2021 Jan;164:102218. Epub 2020 Nov 26. PMID: 33338738; PMCID: PMC7855833. doi: 10.1016/j.plefa.2020.102218
   PubMed Web of Science ®Google Scholar
• Rudmik L, Soler ZM. Medical therapies for adult chronic sinusitis: a systematic review. JAMA. 2015 Sep 1;314(9):926–939. PMID: 26325561. doi: 10.1001/jama.2015.7544
   PubMed Web of Science ®Google Scholar
• Ceballos Cantu JC, Alobid I, Mullol J. Current evaluation and management of patients with chronic rhinosinusitis and nasal polyps. Expert Rev Clin Immunol. 2022 Dec;18(12):1253–1263. Epub 2022 Oct 11. PMID: 36196875. doi: 10.1080/1744666X.2022.2128767
   PubMed Web of Science ®Google Scholar
• Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020 Sep;146:595–605. Epub 2020 Jun 7. Erratum in: J Allergy Clin Immunol. 2021 Jan;147:416. PMID: 32524991. doi: 10.1016/j.jaci.2020.05.032
   PubMed Web of Science ®Google Scholar
• Fokkens W, Trigg A, Lee SE, et al. SYNAPSE study group. Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE study. J Patient Rep Outcomes. 2023 Jan 20;7:4. PMID: 36662344; PMCID: PMC9859976. doi: 10.1186/s41687-023-00543-5
   PubMedGoogle Scholar
• Bachert C, Hellings PW, Mullol J, et al. Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis. Allergy. 2020 Jan;75:148–157. Epub 2019 Oct 23. PMID: 31306495. doi: 10.1111/all.13984
   PubMed Web of Science ®Google Scholar
• Van Bruaene N, Bachert C. Tissue remodeling in chronic rhinosinusitis. Curr Opin Allergy Clin Immunol. 2011 Feb;11:8–11. PMID: 21150430. doi: 10.1097/ACI.0b013e32834233ef
   PubMed Web of Science ®Google Scholar
• Han JK, Kern RC. Topical therapies for management of chronic rhinosinusitis: steroid implants. Int Forum Allergy Rhinol. 2019 May;9(S1):S22–S26. PMID: 31087636. doi: 10.1002/alr.22344
   PubMedGoogle Scholar
• DeConde AS, Mace JC, Alt JA, et al. Investigation of change in cardinal symptoms of chronic rhinosinusitis after surgical or ongoing medical management. Int Forum Allergy Rhinol. 2015 Jan;5(1):36–45. Epub 2014 Sep 18. PMID: 25236780; PMCID: PMC4286292. doi: 10.1002/alr.21410
   PubMed Web of Science ®Google Scholar
• Georgalas C, Cornet M, Adriaensen G, et al. Evidence-based surgery for chronic rhinosinusitis with and without nasal polyps. Curr Allergy Asthma Rep. 2014 Apr;14(4):427. PMID: 24557748. doi: 10.1007/s11882-014-0427-7
   PubMed Web of Science ®Google Scholar
• Alsharif S, Jonstam K, van Zele T, et al. Endoscopic sinus surgery for type-2 CRS wNP: an endotype-based retrospective study. Laryngoscope. 2019 Jun;129:1286–1292. Epub 2019 Jan 21. PMID: 30663058. doi: 10.1002/lary.27815
   PubMed Web of Science ®Google Scholar
• Pirola F, Pace GM, Giombi F, et al. Outcomes of non-mucosa sparing endoscopic sinus surgery (partial reboot) in refractory chronic rhinosinusitis with nasal polyposis: an academic hospital experience. Laryngoscope. 2023 Jul;133:1584–1589. Epub 2022 Oct 6. PMID: 36200712. doi: 10.1002/lary.30422
   PubMed Web of Science ®Google Scholar
• Lee HY, Pyo JS, Kim SJ. Distinct patterns of tissue remodeling and their prognostic role in chronic rhinosinusitis. ORL J Otorhinolaryngol Relat Spec. 2021;83(6):457–463. Epub 2021 Apr 14. PMID: 33853075. doi: 10.1159/000515005
   PubMed Web of Science ®Google Scholar
• Ordovas-Montanes J, Dwyer DF, Nyquist SK, et al. Allergic inflammatory memory in human respiratory epithelial progenitor cells. Nature. 2018 Aug;560(7720):649–654. Epub 2018 Aug 22. PMID: 30135581; PMCID: PMC6133715. doi: 10.1038/s41586-018-0449-8
   PubMed Web of Science ®Google Scholar
• Watelet JB, Bachert C, Gevaert P, et al. Wound healing of the nasal and paranasal mucosa: a review. Am J Rhinol. 2002 Mar;16:77–84. PMID: 12030361.
   PubMedGoogle Scholar
• Gause WC, Wynn TA, Allen JE. Type 2 immunity and wound healing: evolutionary refinement of adaptive immunity by helminths. Nat Rev Immunol. 2013 Aug;13(8):607–614. Epub 2013 Jul 5. PMID: 23827958; PMCID: PMC3789590. doi: 10.1038/nri3476
   PubMed Web of Science ®Google Scholar
• Beule AG. Physiology and pathophysiology of respiratory mucosa of the nose and the paranasal sinuses. GMS Curr Top Otorhinolaryngol Head Neck Surg. 2010;9:Doc07. Epub 2011 Apr 27. PMID: 22073111; PMCID: PMC3199822. doi: 10.3205/cto000071
   PubMedGoogle Scholar
• Barnig C, Bezema T, Calder PC, et al. Activation of resolution pathways to prevent and fight chronic inflammation: lessons from asthma and inflammatory bowel disease. Front Immunol. 2019 Jul 23;10:1699. [Figure 1] Dynamics of the inflammatory response in chronic inflammation [Figure 1] Dynamics of the inflammatory response in chronic inflammation. doi: 10.3389/fimmu.2019.01699
   PubMed Web of Science ®Google Scholar
• Stevens WW, Lee RJ, Schleimer RP, et al. Chronic rhinosinusitis pathogenesis. J Allergy Clin Immunol. 2015 Dec;136(6):1442–1453. PMID: 26654193; PMCID: PMC4680986. doi: 10.1016/j.jaci.2015.10.009
   PubMed Web of Science ®Google Scholar
• Kou W, Hu GH, Yao HB, et al. Regulation of transforming growth factor-β1 activation and expression in the tissue remodeling involved in chronic rhinosinusitis. ORL J Otorhinolaryngol Relat Spec. 2012;74(3):172–178. Epub 2012 Jun 2. PMID: 22678103. doi: 10.1159/000338799
   PubMed Web of Science ®Google Scholar
• Van Bruaene N, PN C, Van Crombruggen K, et al. Inflammation and remodelling patterns in early stage chronic rhinosinusitis. Clin Exp Allergy. 2012 Jun;42:883–890. PMID: 22093003. doi: 10.1111/j.1365-2222.2011.03898.x
   PubMed Web of Science ®Google Scholar
• Galli S, Borregaard N, Wynn T. Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils. Nat Immunol. 2011;12:1035–1044. doi: 10.1038/ni.2109
   PubMed Web of Science ®Google Scholar
• Serhan CN. Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? Am J Pathol. 2010 Oct;177(4):1576–1591. Epub 2010 Sep 2. PMID: 20813960; PMCID: PMC2947253. doi: 10.2353/ajpath.2010.100322
   PubMed Web of Science ®Google Scholar
• Filardy AA, Pires DR, Nunes MP, et al. Proinflammatory clearance of apoptotic neutrophils induces an IL-12(low)IL-10(high) regulatory phenotype in macrophages. J Immunol. 2010 Aug 15;185:2044–2050. Epub 2010 Jul 21. PMID: 20660352. doi: 10.4049/jimmunol.1000017
   PubMed Web of Science ®Google Scholar
• Serhan CN, Yang R, Martinod K, et al. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med. 2009 Jan 16;206(1):15–23. Epub 2008 Dec 22. PMID: 19103881; PMCID: PMC2626672. doi: 10.1084/jem.20081880
   PubMed Web of Science ®Google Scholar
• Schett G, Neurath MF. Resolution of chronic inflammatory disease: universal and tissue-specific concepts. Nat Commun. 2018;9(1):3261. doi: 10.1038/s41467-018-05800-6
   PubMedGoogle Scholar
• Delemarre T, Bochner BS, Simon HU, et al. Rethinking neutrophils and eosinophils in chronic rhinosinusitis. J Allergy Clin Immunol. 2021 Aug;148(2):327–335. Epub 2021 Apr 21. PMID: 33895002; PMCID: PMC8355033. doi: 10.1016/j.jaci.2021.03.024
   PubMed Web of Science ®Google Scholar
• Pérez-Novo CA, Watelet JB, Claeys C, et al. Prostaglandin, leukotriene, and lipoxin balance in chronic rhinosinusitis with and without nasal polyposis. J Allergy Clin Immunol. 2005 Jun;115(6):1189–1196. PMID: 15940133. doi:10.1016/j.jaci.2005.02.029
   PubMed Web of Science ®Google Scholar
• Guilemany JM, Roca-Ferrer J, Mullol J. Cyclooxygenases and the pathogenesis of chronic rhinosinusitis and nasal polyposis. Curr Allergy Asthma Rep. 2008 May;8(3):219–226. PMID: 18589840. doi: 10.1007/s11882-008-0037-3
   PubMed Web of Science ®Google Scholar
• Serhan CN, Levy BD. Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. J Clin Invest. 2018 Jul 2;128(7):2657–2669. Epub 2018 May 14. PMID: 29757195; PMCID: PMC6025982. doi: 10.1172/JCI97943
   PubMed Web of Science ®Google Scholar
• Buckley CD, Gilroy DW, Serhan CN. Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity. 2014 Mar 20;40(3):315–327. PMID: 24656045; PMCID: PMC4004957. doi: 10.1016/j.immuni.2014.02.009
   PubMed Web of Science ®Google Scholar
• Oh SF, Pillai PS, Recchiuti A, et al. Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation. J Clin Invest. 2011 Feb;121(2):569–581. Epub 2011 Jan 4. PMID: 21206090; PMCID: PMC3026718. doi: 10.1172/JCI42545
   PubMed Web of Science ®Google Scholar
• Clària J, Serhan CN. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci U S A. 1995 Oct 10;92:9475–9479. PMID: 7568157; PMCID: PMC40824. doi: 10.1073/pnas.92.21.9475
   PubMed Web of Science ®Google Scholar
• Serhan CN, Hong S, Gronert K, et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med. 2002 Oct 21;196(8):1025–1037. PMID: 12391014; PMCID: PMC2194036. doi: 10.1084/jem.20020760
   PubMed Web of Science ®Google Scholar
• Serhan CN, Arita M, Hong S, et al. Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers. Lipids. 2004 Nov;39(11):1125–1132. PMID: 15726828. doi:10.1007/s11745-004-1339-7.
   PubMed Web of Science ®Google Scholar
• Baker EJ, Miles EA, Burdge GC, et al. Metabolism and functional effects of plant-derived omega-3 fatty acids in humans. Prog Lipid Res. 2016 Oct;64:30–56. Epub 2016 Aug 3. PMID: 27496755. doi: 10.1016/j.plipres.2016.07.002
   PubMed Web of Science ®Google Scholar
• Calder PC. Long-chain fatty acids and inflammation. Proc Nutr Soc. 2012 May;71(2):284–289. Epub 2012 Feb 28. PMID: 22369781. doi: 10.1017/S0029665112000067
   PubMed Web of Science ®Google Scholar
• Cagnina RE, Duvall MG, Nijmeh J, et al. Specialized pro-resolving mediators in respiratory diseases. Curr Opin Clin Nutr Metab Care. 2022 Mar 1;25:67–74. PMID: 34954726; PMCID: PMC8883347. doi: 10.1097/MCO.0000000000000805
   PubMed Web of Science ®Google Scholar
• Owens JM, Shroyer KR, Kingdom TT. Expression of cyclooxygenase and lipoxygenase enzymes in nasal polyps of aspirin-sensitive and aspirin-tolerant patients. Arch Otolaryngol Head Neck Surg. 2006 Jun;132(6):579–587. PMID: 16785401. doi: 10.1001/archotol.132.6.579
   PubMedGoogle Scholar
• Pujols L, Mullol J, Alobid I, et al. Dynamics of COX-2 in nasal mucosa and nasal polyps from aspirin-tolerant and aspirin-intolerant patients with asthma. J Allergy Clin Immunol. 2004 Oct;114(4):814–819. PMID: 15480320. doi: 10.1016/j.jaci.2004.07.050
   PubMed Web of Science ®Google Scholar
• Laidlaw TM, Kidder MS, Bhattacharyya N, et al. Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes. Blood. 2012 Apr 19;119(16):3790–3798. Epub 2012 Jan 18. PMID: 22262771; PMCID: PMC3335383. doi: 10.1182/blood-2011-10-384826
   PubMed Web of Science ®Google Scholar
• Oh SF, Dona M, Fredman G, et al. Resolvin E2 formation and impact in inflammation resolution. J Immunol. 2012 May 1;188(9):4527–4534. Epub 2012 Mar 26. PMID: 22450811; PMCID: PMC3331964. doi: 10.4049/jimmunol.1103652
   PubMed Web of Science ®Google Scholar
• Takano T, Clish CB, Gronert K, et al. Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues. J Clin Invest. 1998 Feb 15;101(4):819–826. PMID: 9466977; PMCID: PMC508630. doi: 10.1172/JCI1578.
   PubMed Web of Science ®Google Scholar
• El Kebir D, Gjorstrup P, Filep JG. Resolvin E1 promotes phagocytosis-induced neutrophil apoptosis and accelerates resolution of pulmonary inflammation. Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):14983–14988. Epub 2012 Aug 27. PMID: 22927428; PMCID: PMC3443132. doi: 10.1073/pnas.1206641109
   PubMed Web of Science ®Google Scholar
• McMahon B, Mitchell S, Brady HR, et al. Lipoxins: revelations on resolution. Trends Pharmacol Sci. 2001 Aug;22(8):391–395. PMID: 11478982. doi: 10.1016/s0165-6147(00)01771-5
   PubMed Web of Science ®Google Scholar
• Levy BD, Romano M, Chapman HA, et al. Human alveolar macrophages have 15-lipoxygenase and generate 15(S)-hydroxy-5,8,11-cis-13-trans-eicosatetraenoic acid and lipoxins. J Clin Invest. 1993 Sep;92(3):1572–1579. PMID: 8376607; PMCID: PMC288306. doi: 10.1172/JCI116738
   PubMed Web of Science ®Google Scholar
• Shimizu S, Ogawa T, Seno S, et al. Pro-resolution mediator lipoxin A4 and its receptor in upper airway inflammation. Ann Otol Rhinol Laryngol. 2013 Nov;122(11):683–689. PMID: 24358628. doi: 10.1177/000348941312201104
   PubMed Web of Science ®Google Scholar
• Shan K, Feng N, Cui J, et al. Resolvin D1 and D2 inhibit tumour growth and inflammation via modulating macrophage polarization. J Cell Mol Med. 2020 24;24(14):8045–8056. https://doi.org/10.1111/jcmm.15436
   PubMed Web of Science ®Google Scholar
• Serhan CN, Dalli J, Karamnov S, et al. Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls pain. Faseb J. 2012 Apr;26(4):1755–1765. Epub 2012 Jan 17. PMID: 22253477; PMCID: PMC3316905. doi: 10.1096/fj.11-201442
   PubMed Web of Science ®Google Scholar
• Vidar Hansen T, Serhan CN. Protectins: their biosynthesis, metabolism and structure-functions. Biochem Pharmacol. 2022 Dec;206:115330. Epub 2022 Oct 28. PMID: 36341938; PMCID: PMC9838224. doi: 10.1016/j.bcp.2022.115330.
   PubMed Web of Science ®Google Scholar
• Isobe Y, Arita M, Matsueda S, et al. Identification and structure determination of novel anti-inflammatory mediator resolvin E3, 17,18-dihydroxyeicosapentaenoic acid. J Biol Chem. 2012 Mar 23;287(13):10525–10534. Epub 2012 Jan 24. PMID: 22275352; PMCID: PMC3322993. doi: 10.1074/jbc.M112.340612
   PubMed Web of Science ®Google Scholar
• Chiang N, Serhan CN. Specialized pro-resolving mediator network: an update on production and actions. Essays Biochem. 2020 Sep 23;64:443–462. PMID: 32885825; PMCID: PMC7682745. doi: 10.1042/EBC20200018
   PubMed Web of Science ®Google Scholar
• Balta MG, Schreurs O, Hansen TV, et al. Expression and function of resolvin RvD1n-3 DPA receptors in oral epithelial cells. Eur J Oral Sci. 2022 Aug;130(4):e12883. Epub 2022 Jul 8. PMID: 35808844; PMCID: PMC9544308. doi: 10.1111/eos.12883
   PubMed Web of Science ®Google Scholar
• Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol. 2008 May;8(5):349–361. PMID: 18437155; PMCID: PMC2744593. doi: 10.1038/nri2294
   PubMed Web of Science ®Google Scholar
• Yang M, Bair JA, Hodges RR, et al. Resolvin E1 reduces leukotriene B4-induced intracellular calcium increase and mucin secretion in rat conjunctival goblet cells. Am J Pathol. 2020 Sep;190:1823–1832. Epub 2020 Jun 16. PMID: 32561135; PMCID: PMC7450248. doi: 10.1016/j.ajpath.2020.06.001
   PubMed Web of Science ®Google Scholar
• Krishnamoorthy S, Recchiuti A, Chiang N, et al. Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1660–1665. Epub 2010 Jan 4. PMID: 20080636; PMCID: PMC2824371. doi: 10.1073/pnas.0907342107
   PubMed Web of Science ®Google Scholar
• Levy BD, Clish CB, Schmidt B, et al. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol. 2001 Jul;2:612–619. PMID: 11429545. doi: 10.1038/89759
   PubMed Web of Science ®Google Scholar
• Kim N, Ramon S, Thatcher TH, et al. Specialized proresolving mediators (SPMs) inhibit human B-cell IgE production. Eur J Immunol. 2016 Jan;46(1):81–91. Epub 2015 Nov 2. PMID: 26474728; PMCID: PMC4710564. doi: 10.1002/eji.201545673
   PubMed Web of Science ®Google Scholar
• Koltsida O, Karamnov S, Pyrillou K, et al. Toll-like receptor 7 stimulates production of specialized pro-resolving lipid mediators and promotes resolution of airway inflammation. EMBO Mol Med. 2013 May;5(5):762–775. Epub 2013 Apr 15. PMID: 23584892; PMCID: PMC3662318. doi: 10.1002/emmm.201201891
   PubMed Web of Science ®Google Scholar
• Liu T, Kanaoka Y, Barrett NA, et al. Aspirin-exacerbated respiratory disease involves a cysteinyl leukotriene-driven il-33-mediated mast cell activation pathway. J Immunol. 2015 Oct 15;195:3537–3545. Epub 2015 Sep 4. PMID: 26342029; PMCID: PMC4592820. doi: 10.4049/jimmunol.1500905
   PubMed Web of Science ®Google Scholar
• Liu T, Laidlaw TM, Katz HR, et al. Prostaglandin E2 deficiency causes a phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes. Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):16987–16992. Epub 2013 Oct 1. PMID: 24085850; PMCID: PMC3801005. doi: 10.1073/pnas.1313185110
   PubMed Web of Science ®Google Scholar
• Miyata J, Fukunaga K, Kawashima Y, et al. Dysregulated metabolism of polyunsaturated fatty acids in eosinophilic allergic diseases. Prostaglandins Other Lipid Mediat. 2020 Oct;150:106477. Epub 2020 Jul 23. PMID: 32711128. doi: 10.1016/j.prostaglandins.2020.106477
   PubMed Web of Science ®Google Scholar
• Pace S, Zhang K, Jordan PM, et al. Anti-inflammatory celastrol promotes a switch from leukotriene biosynthesis to formation of specialized pro-resolving lipid mediators. Pharmacol Res. 2021 May;167:105556. Epub 2021 Mar 31. PMID: 33812006. doi: 10.1016/j.phrs.2021.105556
   PubMed Web of Science ®Google Scholar
• Kristjansson RP, Benonisdottir S, Davidsson OB, et al. A loss-of-function variant in ALOX15 protects against nasal polyps and chronic rhinosinusitis. Nat Genet. 2019 Feb;51(2):267–276. Epub 2019 Jan 14. PMID: 30643255. doi: 10.1038/s41588-018-0314-6
   PubMed Web of Science ®Google Scholar
• Laulajainen-Hongisto A, Lyly A, Hanif T, et al. Genomics of asthma, allergy and chronic rhinosinusitis: novel concepts and relevance in airway mucosa. Clin Transl Allergy. 2020 Oct 28;10(1):45. PMID: 33133517; PMCID: PMC7592594. doi: 10.1186/s13601-020-00347-6
   PubMed Web of Science ®Google Scholar
• Levy JM, Rudmik L, Peters AT, et al. Contemporary management of chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease: an evidence-based review with recommendations. Int Forum Allergy Rhinol. 2016;6(12):1273–1283. doi: 10.1002/alr.21826
   PubMed Web of Science ®Google Scholar
• Sham HP, Walker KH, Abdulnour RE, et al. 15-epi-Lipoxin A4, resolvin D2, and resolvin D3 induce NF-kappaB regulators in bacterial pneumonia. J Immunol. 2018;200:2757–2766. doi: 10.4049/jimmunol.1602090
   PubMed Web of Science ®Google Scholar
• Ruiz A, Sarabia C, Torres M, et al. Resolvin D1 (RvD1) and maresin 1 (Mar1) contribute to human macrophage control of M. tuberculosis infection while resolving inflammation. Int Immunopharmacol. 2019;74:105694. doi: 10.1016/j.intimp.2019.105694
   PubMed Web of Science ®Google Scholar
• Zhu ZZ, Wang WQ, Han JB, et al. Different concentrations of specialized pro-resolving mediators in eosinophilic and non-eosinophilic chronic rhinosinusitis with nasal polyps. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2021 Oct 7;56:1073–1079. Chinese Chinese. doi: 10.3760/cma.j.cn115330-20210419-00212
   PubMedGoogle Scholar
• Schneider TR, Johns CB, Palumbo ML, et al. Dietary fatty acid modification for the treatment of aspirin-exacerbated respiratory disease: a prospective pilot trial. J Allergy Clin Immunol Pract. 2018 May;6(3):825–831. Epub 2017 Nov 10. PMID: 29133219; PMCID: PMC5945343. doi: 10.1016/j.jaip.2017.10.011
   PubMed Web of Science ®Google Scholar
• Attia TM. Role of omega-3 polyunsaturated fatty acids in treatment of nasal polyposis. Am J Rhinol Allergy. 2020 Jan;34:43–49. Epub 2019 Aug 21. PMID: 31433665. doi: 10.1177/1945892419871802
   PubMed Web of Science ®Google Scholar